Cystic fibrosis

Research output: Contribution to journalArticle

Abstract

• On the basis of consensus, (11) the diagnosis of cystic fibrosis (CF) is based on (1) the presence of one or more characteristic phenotypic features of chronic, recurrent sinopulmonary disease, nutritional and gastrointestinal abnormalities, male urogenital abnormalities, and salt depletion syndromes; (2) a family history of CF in a sibling; and (3) a positive newborn screening test result associated with laboratory-demonstrated evidence of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, such as abnormal sweat chloride concentration, identification of 2 disease-causing CFTR mutations, or demonstration in vivo of characteristic ion transport abnormalities. • On the basis of consensus, (40) annual oral glucose tolerance tests are recommended for people with CF older than 9 years to screen for CF-related diabetes mellitus. • On the basis of research evidence, (21)(22) the long-term therapies to maintain optimal lung health for children and adults with CF include control of chronic airways infection and inflammation, clearance of mucous secretions, and, where clinically applicable, treatments aimed at the basic CF genetic defect. • On the basis of strong research evidence, (24)(25) treatment with ivacaftor, the first US Food and Drug Administration-approved drug that targets the basic CF genetic defect, resulted in improvements in lung function, weight, quality of life, and sweat chloride levels and reduction in exacerbation frequency in people with CF carrying at least one G551D mutation.

Original languageEnglish (US)
Pages (from-to)194-205
Number of pages12
JournalPediatrics in review / American Academy of Pediatrics
Volume35
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Cystic Fibrosis
Cystic Fibrosis Transmembrane Conductance Regulator
Sweat
Chlorides
Consensus
Urogenital Abnormalities
Lung
Mutation
Airway Management
Gastrointestinal Diseases
Ion Transport
United States Food and Drug Administration
Glucose Tolerance Test
Research
Siblings
Diabetes Mellitus
Therapeutics
Salts
Quality of Life
Newborn Infant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Cite this

Cystic fibrosis. / Paranjape, Shruti M; Mogayzel, Peter.

In: Pediatrics in review / American Academy of Pediatrics, Vol. 35, No. 5, 2014, p. 194-205.

Research output: Contribution to journalArticle

@article{7e19d2e535c548acb81df2ab3f6ee2e4,
title = "Cystic fibrosis",
abstract = "• On the basis of consensus, (11) the diagnosis of cystic fibrosis (CF) is based on (1) the presence of one or more characteristic phenotypic features of chronic, recurrent sinopulmonary disease, nutritional and gastrointestinal abnormalities, male urogenital abnormalities, and salt depletion syndromes; (2) a family history of CF in a sibling; and (3) a positive newborn screening test result associated with laboratory-demonstrated evidence of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, such as abnormal sweat chloride concentration, identification of 2 disease-causing CFTR mutations, or demonstration in vivo of characteristic ion transport abnormalities. • On the basis of consensus, (40) annual oral glucose tolerance tests are recommended for people with CF older than 9 years to screen for CF-related diabetes mellitus. • On the basis of research evidence, (21)(22) the long-term therapies to maintain optimal lung health for children and adults with CF include control of chronic airways infection and inflammation, clearance of mucous secretions, and, where clinically applicable, treatments aimed at the basic CF genetic defect. • On the basis of strong research evidence, (24)(25) treatment with ivacaftor, the first US Food and Drug Administration-approved drug that targets the basic CF genetic defect, resulted in improvements in lung function, weight, quality of life, and sweat chloride levels and reduction in exacerbation frequency in people with CF carrying at least one G551D mutation.",
author = "Paranjape, {Shruti M} and Peter Mogayzel",
year = "2014",
doi = "10.1542/pir.35-5-194",
language = "English (US)",
volume = "35",
pages = "194--205",
journal = "Pediatrics in Review",
issn = "0191-9601",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - Cystic fibrosis

AU - Paranjape, Shruti M

AU - Mogayzel, Peter

PY - 2014

Y1 - 2014

N2 - • On the basis of consensus, (11) the diagnosis of cystic fibrosis (CF) is based on (1) the presence of one or more characteristic phenotypic features of chronic, recurrent sinopulmonary disease, nutritional and gastrointestinal abnormalities, male urogenital abnormalities, and salt depletion syndromes; (2) a family history of CF in a sibling; and (3) a positive newborn screening test result associated with laboratory-demonstrated evidence of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, such as abnormal sweat chloride concentration, identification of 2 disease-causing CFTR mutations, or demonstration in vivo of characteristic ion transport abnormalities. • On the basis of consensus, (40) annual oral glucose tolerance tests are recommended for people with CF older than 9 years to screen for CF-related diabetes mellitus. • On the basis of research evidence, (21)(22) the long-term therapies to maintain optimal lung health for children and adults with CF include control of chronic airways infection and inflammation, clearance of mucous secretions, and, where clinically applicable, treatments aimed at the basic CF genetic defect. • On the basis of strong research evidence, (24)(25) treatment with ivacaftor, the first US Food and Drug Administration-approved drug that targets the basic CF genetic defect, resulted in improvements in lung function, weight, quality of life, and sweat chloride levels and reduction in exacerbation frequency in people with CF carrying at least one G551D mutation.

AB - • On the basis of consensus, (11) the diagnosis of cystic fibrosis (CF) is based on (1) the presence of one or more characteristic phenotypic features of chronic, recurrent sinopulmonary disease, nutritional and gastrointestinal abnormalities, male urogenital abnormalities, and salt depletion syndromes; (2) a family history of CF in a sibling; and (3) a positive newborn screening test result associated with laboratory-demonstrated evidence of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, such as abnormal sweat chloride concentration, identification of 2 disease-causing CFTR mutations, or demonstration in vivo of characteristic ion transport abnormalities. • On the basis of consensus, (40) annual oral glucose tolerance tests are recommended for people with CF older than 9 years to screen for CF-related diabetes mellitus. • On the basis of research evidence, (21)(22) the long-term therapies to maintain optimal lung health for children and adults with CF include control of chronic airways infection and inflammation, clearance of mucous secretions, and, where clinically applicable, treatments aimed at the basic CF genetic defect. • On the basis of strong research evidence, (24)(25) treatment with ivacaftor, the first US Food and Drug Administration-approved drug that targets the basic CF genetic defect, resulted in improvements in lung function, weight, quality of life, and sweat chloride levels and reduction in exacerbation frequency in people with CF carrying at least one G551D mutation.

UR - http://www.scopus.com/inward/record.url?scp=84899825299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899825299&partnerID=8YFLogxK

U2 - 10.1542/pir.35-5-194

DO - 10.1542/pir.35-5-194

M3 - Article

C2 - 24790073

AN - SCOPUS:84899825299

VL - 35

SP - 194

EP - 205

JO - Pediatrics in Review

JF - Pediatrics in Review

SN - 0191-9601

IS - 5

ER -